Drug Combination Details
| General Information of the Combination (ID: C21577) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | Trametinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Melanoma
[ICD-11: 2C30]
|
Investigative | [1] | ||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | D04 | CVCL_H604 | Melanoma | Homo sapiens | ||
| MM415 | CVCL_2608 | Melanoma | Homo sapiens | |||
| MM485 | CVCL_2610 | Melanoma | Homo sapiens | |||
| SK-MEL-2 | CVCL_0069 | Melanoma | Homo sapiens | |||
| MaMel30I | CVCL_A165 | Melanoma | Homo sapiens | |||
| MaMel27II | CVCL_A163 | Melanoma | Homo sapiens | |||
| Experimental
Result(s) |
Metformin and trametinib combinations are effective in preclinical models and may be a possible option for treatment of NRAS mutant cancers. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | PRKAA2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | VOA1056 | CVCL_V536 | Adenocarcinoma | Homo sapiens | ||
| VOA1312 | CVCL_V538 | Adenocarcinoma | Homo sapiens | |||
| VOA5646 | CVCL_VQ39 | Adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Metformin and trametinib combination showed synergistic inhibition of RAS mutated VOA1312 and VOA1056 cells, but not for non-Ras mutated VOA5646 cells. | |||||
